What Has Been the Growth Trajectory for the Anti-Hypertensive Drugs Market in Recent Years?
The anti-hypertensive drugs market has seen considerable growth due to a variety of factors.
• The market size of anti-hypertensive drugs has been progressively expanding over recent years. The market which was valued at $36.66 billion in 2024 is projected to reach $37.5 billion in 2025, with a compound annual growth rate (CAGR) of 2.3%.
The factors contributing to the growth during the historical period can be traced back to environmental and lifestyle factors, past market competition, traditional treatment preferences, economic circumstances, and global health trends of the past.
What Is the Forecasted Market Size and Growth Rate for The Anti-Hypertensive Drugs Market?
The anti-hypertensive drugs market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, a slight increase is forecasted in the market size of anti-hypertensive drugs, expanding to a projected size of $40.41 billion in 2029, at a compound annual growth rate (CAGR) of 1.9%.
Factors contributing to the anticipated growth in this period include affordability and cost-effectiveness, progress in therapeutic advancements, changes in disease patterns, regulatory alterations and approvals, shifts in aging population, and modifications in healthcare policies and reimbursement. Key trends to look out for during the forecast period encompass therapeutic advancements, changes in disease prevalence, regulatory environment, healthcare policies, and growth in diagnosis and monitoring techniques.
Which Key Drivers Are Propelling Th Anti-Hypertensive Drugs Market's Growth?
The surge in the anti-hypertensive drug market is largely driven by a sedentary lifestyle. Factors like consuming unhealthy food, insufficient hints of a well-rounded diet, and irregular sleep patterns due to inconsistent work schedules are all contributing to the rise in hypertension. Hypertension is responsible for a significant number of deaths associated with heart disease (45%) and stroke (51%). Once diagnosed with hypertension, patients need to regularly use medication to manage it, depending on the severity. For example, as per records from the National Health Service, a government department based in England, in May 2023, hypertension's prevalence increases with age, beginning at 9% for adults aged 16-44 and surging to 60% for those aged 65 and above. This trend sets a steady demand for the product, acting as a significant contributor to the anti-hypertensive drug market's expansion.
What Key Areas Define The Segmentation Of The Global Anti-Hypertensive Drugs Market?
The anti-hypertensive drugs market covered in this report is segmented –
1) By Therapeutics: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators
2) By Disease Source: Primary Hypertension, Secondary Hypertension
3) By End Users: Hospitals, Clinics, Homecare
Subsegments:
1) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
2) By Angiotensin Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Candesartan
3) By Angiotensin Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Benazepril
4) By Beta Blockers: Metoprolol, Atenolol, Carvedilol, Bisoprolol
5) By Alpha Blockers: Doxazosin, Prazosin, Terazosin
6) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil, Nifedipine
7) By Renin Inhibitors: Aliskiren
8) By Vasodilators: Hydralazine, Minoxidil
Pre-Book The Anti-Hypertensive Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Anti-Hypertensive Drugs Market?
In the anti-hypertensive drugs market, significant businesses are striving for an advantage by developing new products, such as Metoprolol Succinate Extended-Release Tablets. These tablets are utilized for hypertension treatment. In June 2023, for example, Granules India Limited, a pharmaceutical manufacturer from India, introduced Metoprolol Succinate Extended-Release Tablets, approved by the US-based Food and Drug Administration (FDA). Designed as anti-hypertensive medication, Metoprolol Succinate Extended-Release Tablets help decrease high blood pressure. Available in multiple strengths such as 25mg, 50mg, 100mg, and 200mg, they contain beta-blockers that relax the heart rate, lessen the heart's workload, and reduce blood pressure.
Who Are the Key Players in the Anti-Hypertensive Drugs Market?
Major companies operating in the anti-hypertensive drugs market include:
• Pfizer Inc.
• Johnson & Johnson Ltd.
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• AbbiVe Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Astra Zeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• C.H. Boehringer Sohn AG & Ko. KG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Daiichi Sankyo Company Limited
• Fresenius Kabi AG
• Sun Pharmaceuticals LLC
• Cipla Limited
• Dr. Reddy's Laboratories
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Torrent Pharmaceuticals Ltd
• Noden Pharma DAC
• Actelion Pharmaceuticals Ltd.
What Is The Most Dominant Region In The Anti-Hypertensive Drugs Market?
North America was the largest region in the anti-hypertensive drugs market in 2024. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the anti-hypertensive drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
